Skip to main content

Table 1 Gefitinib-induced growth inhibition in combination with ATRA in NSCLC/ADC cells

From: All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells

Cell line

n

Gefitinib

Gefitinib plus ATRA treatment

IC50 (μmol/L)

P

IC50 (μmol/L)

P

A549

3

8.42 ± 0.312

–

–

–

A549GSC

3

36.97 ± 2.017

< 0.01

18.17 ± 1.271

< 0.01

H1650

3

5.26 ± 0.204

–

–

–

H1650GSC

3

27.11 ± 1.891

< 0.01

11.94 ± 1.153

< 0.01

  1. NSCLC/ADC cells were treated with vehicle or gefitinib and treated with ATRA (10 μmol/L) plus gefitinib for 72 hoursh. Relative number of viable cells was assayed using crystal violet assay. IC50 values were measured as a curvilinear regression equation for each survival curve. Data represent mean values ± S.D. from three independent experiments. *P values, compared with gefitinib alone
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us